Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
NCT01451450 · Novartis Pharmaceuticals · PHASE2 · withdrawn · last registry update 2012-07-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-06-07Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), omalizumab + omalizumab placebo (NCT00377572)
- 2013-03-27Results posted on the registry: Genentech, Inc., Omalizumab + Placebo (NCT00495612)
- 2013-03-04Phase 3 first posted: Insel Gruppe AG, University Hospital Bern, Omalizumab (Xolair) + Placebo (NCT01803763)
- 2013-01-21Also stopped (terminated): Genentech, Inc., Xolair (omalizumab) (NCT00086606)
- 2013-01-18Results posted on the registry: Novartis Pharmaceuticals, omalizumab at a dose of 0.016mg/kg/IU/mL + Placebo (NCT00670930)
- 2012-11-07Phase 3 first posted: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT01723072)
- 2012-10-16Results posted on the registry: University of Iowa, Omalizumab + prednisone (NCT00472030)
- 2012-06-08Results posted on the registry: Novartis Pharmaceuticals, omalizumab + Placebo (NCT01007149)
- 2011-12-08Results posted on the registry: Genentech, Inc., omalizumab (Xolair) + placebo (NCT00096954)
- 2011-11-17Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT00870584)
- 2011-10-21Results posted on the registry: Novartis, Omalizumab 75-375 mg + Placebo to omalizumab (NCT00481676)
- 2011-10-13Results posted on the registry: Genentech, Inc., omalizumab (Xolair) + placebo (NCT00314574)
- 2011-09-26Also stopped (terminated): Novartis Pharmaceuticals, Omalizumab + Placebo (NCT00787917)
- 2011-09-09Results posted on the registry: Genentech, Inc., omalizumab + placebo (NCT00866788)
- 2011-08-04Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT00787917)
- 2011-08-03Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT00079937)
- 2011-08-01Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + placebo (NCT00454051)
- 2011-07-25Results posted on the registry: Novartis, Omalizumab (NCT00264849)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision